PKM and lung cancer: Lung cancer cells are characterized by expression of a dimeric form of PKM2 which implies that all glycolytic intermediates preceding PKM2 activity accumulate and are directed into biosynthetic processes, such as nucleotide-, lipid- and serine/glycine synthesis which stimulates tumor proliferation as demonstrated in Figure 1 (27–29).